目的 觀察銀杏二萜內(nèi)酯葡胺注射液（DGMI）對急性缺血性腦卒中（AIS）再通成功患者預(yù)后的影響。方法 回顧性選取南京大學(xué)醫(yī)學(xué)院附屬鼓樓醫(yī)院和南京醫(yī)科大學(xué)第一附屬醫(yī)院2016年6月-2021年12月收治的AIS再通治療患者為研究對象，共納入頸內(nèi)動脈或大腦中動脈閉塞者206例。根據(jù)再通治療后3 d頭顱磁共振血管造影（MRA）檢查結(jié)果，將206例患者分為開通成功患者（n=157，其中61例接受DGMI治療）和開通失敗患者（n=49，其中21接例受DGMI治療）；以患者是否接受過DGMI治療為依據(jù)，將接受DGMI治療≥7 d的患者設(shè)為試驗組（n=82），未接受DGMI治療的為對照組（n=124）。收集的臨床資料包括年齡、性別、發(fā)病至干預(yù)時間、干預(yù)方式、不良事件（癥狀性腦出血、死亡）、發(fā)病時和90 d的美國國立衛(wèi)生研究院卒中量表（NIHSS）評分和改良Rankin評分量表（mRS）評分。分別比較開通成功患者和開通失敗患者中對照組和試驗組間不良事件發(fā)生率和預(yù)后的差異，包括癥狀性腦出血率、死亡率，以及90 d后的NIHSS改善率和mRS評分。結(jié)果 開通成功患者中，試驗組90 d NIHSS改善率和mRS評分均明顯優(yōu)于對照組（P＜0.05）；而在開通失敗患者中兩組間90 d NIHSS改善率和mRS評分比較，差異無統(tǒng)計學(xué)意義（P＞0.05）；對照組和試驗組的癥狀性腦出血率和死亡率在兩亞組中均無明顯差異（P＞0.05）。結(jié)論 對于接受再通治療的AIS患者，DGMI有利于再通成功患者的神經(jīng)功能改善，且不增加不良事件發(fā)生風(fēng)險。

Objective To study the effect of Diterpene Ginkgolides Meglumine Injection(DGMI) on the prognosis of patients with successful recanalization of acute ischemic stroke (AIS). Methods A total of 206 patients with internal carotid artery or middle cerebral artery occlusion who were admitted to the Nanjing Drum Tower Hospital Affiliated Hospital of Nanjing University Medical School and the First Affiliated Hospital of Nanjing Medical University from June 2016 to December 2021 were selected as the study subjects. According to the results of skull magnetic resonance angiography (MRA) three days after recanalization treatment, 206 patients were divided into two groups: successful patients (n= 157, of which 61 were treated with DGMI) and failed patients (n= 49, of which 21 were treated with DGMI). Based on whether the patients have received DGMI treatment, the patients who have received DGMI treatment for ≥ 7 days are set as the experimental group (n= 82), and the patients who have not received DGMI treatment are set as the control group (n= 124). The clinical data collected included age, sex, time from onset to intervention, intervention mode, adverse events (symptomatic cerebral hemorrhage, death), the National Institutes of Health Stroke Scale (NIHSS) score and the modified Rankin Scale (mRS) score at the time of onset and 90 days. The difference in the incidence of adverse events and prognosis between the control group and the experimental group, including the rate of symptomatic intracerebral hemorrhage, mortality, and the improvement rate of NIHSS and mRS score after 90 days, were compared between the patients with successful and failed opening. Results The improvement rate of NIHSS and mRS score in the experimental group at 90 days were significantly better than those in the control group (P< 0.05). However, there was no significant difference between the two groups in the improvement rate of NIHSS and mRS score at 90 days in patients with failed opening (P> 0.05). There was no significant difference in the rate of symptomatic intracerebral hemorrhage and mortality between the two groups (P> 0.05). Conclusion For AIS patients receiving recanalization treatment, DGMI is beneficial to the improvement of neurological function in patients with successful recanalization without increasing the risk of adverse events.

R971

國家自然科學(xué)基金項目（81901253）；江蘇省衛(wèi)健委面上項目（H2019108）